vs
博士伦健康（BHC）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是Roper Technologies的1.3倍（$2.8B vs $2.1B），Roper Technologies净利率更高（15.8% vs -3.7%，领先19.5%），Roper Technologies同比增速更快（11.3% vs 9.3%），Roper Technologies自由现金流更多（$507.0M vs $403.0M），过去两年博士伦健康的营收复合增速更高（14.0% vs 10.5%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
BHC vs ROP — 直观对比
营收规模更大
BHC
是对方的1.3倍
$2.1B
营收增速更快
ROP
高出2.0%
9.3%
净利率更高
ROP
高出19.5%
-3.7%
自由现金流更多
ROP
多$104.0M
$403.0M
两年增速更快
BHC
近两年复合增速
10.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $2.1B |
| 净利润 | $-103.0M | $331.0M |
| 毛利率 | — | 69.4% |
| 营业利润率 | 17.0% | 27.2% |
| 净利率 | -3.7% | 15.8% |
| 营收同比 | 9.3% | 11.3% |
| 净利润同比 | -205.1% | 842.6% |
| 每股收益（稀释后） | $-0.30 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.8B | $2.1B | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.3B | $1.9B | ||
| Q4 24 | $2.6B | $1.9B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.4B | $1.7B |
净利润BHCROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $-103.0M | $428.4M | ||
| Q3 25 | $179.0M | $398.5M | ||
| Q2 25 | $148.0M | $378.3M | ||
| Q1 25 | $-58.0M | $331.1M | ||
| Q4 24 | $98.0M | $462.3M | ||
| Q3 24 | $-85.0M | $367.9M | ||
| Q2 24 | $10.0M | $337.1M |
毛利率BHCROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | — | 69.5% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | — | 69.2% | ||
| Q1 25 | — | 68.7% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 69.2% | ||
| Q2 24 | — | 69.5% |
营业利润率BHCROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | 17.0% | 28.6% | ||
| Q3 25 | 23.1% | 28.4% | ||
| Q2 25 | 17.5% | 28.2% | ||
| Q1 25 | 12.2% | 27.9% | ||
| Q4 24 | 21.8% | 28.0% | ||
| Q3 24 | 12.7% | 28.1% | ||
| Q2 24 | 16.2% | 28.8% |
净利率BHCROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | -3.7% | 20.8% | ||
| Q3 25 | 6.7% | 19.8% | ||
| Q2 25 | 5.8% | 19.5% | ||
| Q1 25 | -2.6% | 17.6% | ||
| Q4 24 | 3.8% | 24.6% | ||
| Q3 24 | -3.4% | 20.8% | ||
| Q2 24 | 0.4% | 19.6% |
每股收益（稀释后）BHCROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $-0.30 | $3.97 | ||
| Q3 25 | $0.48 | $3.68 | ||
| Q2 25 | $0.40 | $3.49 | ||
| Q1 25 | $-0.16 | $3.06 | ||
| Q4 24 | $0.24 | $4.29 | ||
| Q3 24 | $-0.23 | $3.40 | ||
| Q2 24 | $0.03 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $382.9M |
| 总债务越低越好 | $20.8B | $9.7B |
| 股东权益账面价值 | $-554.0M | $18.8B |
| 总资产 | $26.4B | $34.6B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资BHCROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $1.3B | $297.4M | ||
| Q3 25 | $1.3B | $320.0M | ||
| Q2 25 | $1.7B | $242.4M | ||
| Q1 25 | $1.1B | $372.8M | ||
| Q4 24 | $1.2B | $188.2M | ||
| Q3 24 | $719.0M | $269.6M | ||
| Q2 24 | $595.0M | $251.5M |
总债务BHCROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $20.8B | $9.3B | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | $7.6B | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — |
股东权益BHCROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $-554.0M | $19.9B | ||
| Q3 25 | $-565.0M | $20.0B | ||
| Q2 25 | $-764.0M | $19.6B | ||
| Q1 25 | $-1.2B | $19.2B | ||
| Q4 24 | $-1.3B | $18.9B | ||
| Q3 24 | $-1.2B | $18.5B | ||
| Q2 24 | $-1.2B | $18.1B |
总资产BHCROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $26.4B | $34.6B | ||
| Q3 25 | $26.8B | $34.6B | ||
| Q2 25 | $27.3B | $33.2B | ||
| Q1 25 | $26.4B | $31.4B | ||
| Q4 24 | $26.5B | $31.3B | ||
| Q3 24 | $26.5B | $31.6B | ||
| Q2 24 | $26.5B | $29.8B |
负债/权益比BHCROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | — |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $507.0M |
| 自由现金流率自由现金流/营收 | 14.4% | 24.2% |
| 资本支出强度资本支出/营收 | 3.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流BHCROP
| Q1 26 | — | — | ||
| Q4 25 | $495.0M | $738.0M | ||
| Q3 25 | $405.0M | $869.5M | ||
| Q2 25 | $289.0M | $404.1M | ||
| Q1 25 | $211.0M | $528.7M | ||
| Q4 24 | $601.0M | $722.2M | ||
| Q3 24 | $405.0M | $755.4M | ||
| Q2 24 | $380.0M | $384.1M |
自由现金流BHCROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $403.0M | — | ||
| Q3 25 | $314.0M | — | ||
| Q2 25 | $190.0M | — | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $495.0M | — | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | — |
自由现金流率BHCROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 14.4% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | — |
资本支出强度BHCROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 3.3% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | — |
现金转化率BHCROP
| Q1 26 | — | — | ||
| Q4 25 | — | 1.72× | ||
| Q3 25 | 2.26× | 2.18× | ||
| Q2 25 | 1.95× | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | 6.13× | 1.56× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | 38.00× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
ROP
暂无分部数据
